According to the sources provided, Vascepa (icosapent ethyl) is a prescription drug used to treat high triglyceride levels in adults. The drug is manufactured by Amarin Corporation and was approved by Health Canada in 2020 [3].

However, there is no information available on the cost of Vascepa in Canada. The first source provides information on the patent status and expiration date of the drug, while the second source discusses the clinical trials and effectiveness of the drug in treating high triglyceride levels. The third source is an investor update from HLS Therapeutics, the company responsible for launching Vascepa in Canada, but it does not mention the cost of the drug.

It is important to note that drug prices in Canada are regulated by the Patented Medicine Prices Review Board (PMPRB), which sets a maximum price that drug manufacturers can charge for patented drugs [2]. The price of Vascepa may vary depending on factors such as dosage, location, and insurance coverage.

In conclusion, while the sources provided offer valuable information on Vascepa and its approval in Canada, there is no specific information available on the cost of the drug. Patients are advised to consult with their healthcare provider and insurance provider for more information on the cost and availability of Vascepa in Canada.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.ncbi.nlm.nih.gov/books/NBK566005/
[3] https://www.newswire.ca/news-releases/hls-therapeutics-provides-investor-update-on-the-canadian-launch-of-vascepa-r-icosapent-ethyl--891852629.html